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Myocardial infarction is the leading cause of death in the Western world and a major health-care burden. Treatments have evolved rapidly over the past 50 years, but myocardial infarction remains an unpredictable event and one that is frequently the first clinical manifest ation of the underlying atherosclerotic disease process. Cardiovascular risk scores based on traditional risk factors are widely employed, but they remain imprecise in estimating the risk of myocardial infarction on an individual basis. The same is true of established imaging techniques, which have largely been developed to identify patients with angina who might derive symptomatic benefit from revascularization. Rapid developments in coronary as well as myocardial imaging have the potential not only to improve our understanding of the processes leading to myocardial infarction, but also to deliver accurate, personalized prognostic stratification and improved patient outcomes.
Advances have occurred in a variety of both invasive and noninvasive imaging modalities. Invasive coronary imaging relies on gaining access to the arterial system and administering contrast media and specifically designed catheters into the coronary vessels. Advances in catheter design and technology now allow for an array of additional invasive approaches, beyond the standard assessments of luminal stenosis. For example, coronary physiology can be routinely assessed using fractional flow reserve (FFR), whereas coronary plaque imaging has become possible using intravascular ultrasonography (IVUS), and, more recently, optical coherence tomography (OCT), near-infrared spectroscopy (NIRS), and near-infrared fluorescence (NIRF). Each approach provides different capacities and potentially complementary information. Noninvasive imaging has undergone similar developments. In assessing physiology, absolute quantification of myocardial blood flow has become possible, and detailed coronary plaque imaging is now feasible through developments in computed tomo graphy (CT), cardiovascular magnetic resonance imaging (MRI), and positron emission tomography (PET).
In combination, this breadth of imaging technologies can provide a comprehensive, multifaceted evaluation of coronary atherosclerosis. In particular, we can directly evaluate and visualize the functional severity of individual luminal stenoses, the overall plaque burden, highrisk plaque characteristics, and even disease activity as Abstract | Coronary atherosclerosis and the precipitation of acute myocardial infarction are highly complex processes, which makes accurate risk prediction challenging. Rapid developments in invasive and noninvasive imaging technologies now provide us with detailed, exquisite images of the coronary vasculature that allow direct investigation of a wide range of these processes. These modalities include sophisticated assessments of luminal stenoses and myocardial perfusion, complemented by novel measures of the atherosclerotic plaque burden, adverse plaque characteristics, and disease activity. Together, they can provide comprehensive, individualized assessments of coronary atherosclerosis as it occurs in patients. Not only can this information provide important pathological insights, but it can also potentially be used to guide personalized treatment decisions. In this Review, we describe the latest advances in both established and emerging imaging techniques, focusing on the strengths and weakness of each approach. Moreover, we discuss how these technological advances might be translated from attractive images into novel imaging strategies and definite improvements in clinical risk prediction and patient outcomes. This process will not be easy, and the many potential barriers and difficulties are also reviewed.
atherosclerosis proceeds in patients. In this Review, we describe the capacity of established and emerging imaging modalities to inform about each of these important areas, their relative strengths and weaknesses, and how they are currently employed in clinical practice (TABLE 1) . Importantly, we also discuss how these advances might be used in the future, highlighting the potential for synergy between the different approaches, but also the many barriers that exist to future translation. A new era of advanced imaging and precision medicine for atherosclerosis seems imminent, but its realization will be far from straightforward.
Pathology
Coronary atherosclerosis is an almost invariable pathological finding from middle age onwards. Atherosclerosis is characterized by lipid deposition and modification within the vessel wall, and is frequently accompanied by inflammation and vascular matrix remodelling within discrete coronary plaques 1 . These lesions can result in progressive obstruction of the coronary vascular lumen, causing symptoms of angina owing to myocardial ischaemia. Alternatively, sudden plaque rupture or erosion of individual lesions can precipitate coronary thrombosis and acute myocardial infarction 2 . Improving our understanding of the processes leading to plaque rupture and erosion is, therefore, critical, with imaging well positioned to advance this knowledge.
Atherosclerosis is initiated by the deposition of LDL within the arterial intima, most frequently at sites of low shear stress and endothelial dysfunction 3 . This lipid subsequently becomes oxidized, which triggers an inflammatory response consisting predominantly of macrophages that engulf lipid particles to form foam cells 4 . These initial lesions often remain static for many years or even regress. However, in the presence of particular environmental insults and immune system imbalances, proinflammatory cellular phenotypes become established and promote ongoing inflammation, cell death, and proteolysis. Ultimately, these processes drive progression towards the complex coronary lesions that are predisposed to acute plaque rupture and adverse events.
Ruptured culprit plaques frequently have speci fic histo pathological characteristics, typified by the so-called thin-cap fibroatheroma (TCFA). These features include extensive inflammation, a large necrotic core, a thin fibrous cap, positive remodelling with a large plaque volume, and microcalcification. The necrotic core forms as a consequence of accelerated extracellular lipid depo sition, increasing inflammation, oxidative stress, hypoxia, and cell death 4 . The core is separated from the lumen by a fibrous cap. In inflamed lesions, this cap becomes thinned and weakened by the action of matrix metalloproteinases, predisposing it to rupture at sites of increased mechanical stress 3 . The consequent exposure of the necrotic core to the circulating blood can lead to extensive and occlusive thrombus formation causing myocardial infarction. Alternatively, a less pronounced thrombogenic reaction can ensue, resulting instead in subclinical rupture, healing, and plaque growth. The factors dictating the magnitude of this thrombotic reaction are not well understood, but seem to be related to character istics in both the blood and plaque composition 2 . Constant tension exists between pro inflammatory forces and attempts by the body to heal and stabilize the coronary vasculature. Smooth muscle cells migrate from the arterial media and secrete components of fibrous matrix to strengthen the fibrous cap. Calcification also seems to occur as a healing response to the intense necrotic inflammation and cell death, and to be mediated by extracellular vesicles. However, the process occurs in two steps: microcalcification in the initial stages is associated with inflamed, potentially unstable plaques, whereas macroscopic calcification in the later stages seems to impart stability 5 . Mechanistic studies support this hypothesis, with early-stage microcalcification closely associated with macrophage inflammatory activity (R 2 = 0.93) and cell death, and regions of advanced calcification existing remotely from areas of inflam mation [6] [7] [8] . If the processes of fibrosis and macro calcification prevail, a thick-cap fibroatheroma or heavily calcified lesion can form, effectively walling off the necrotic core from the blood pool. Conversely, in the presence of ongoing macrophage infiltration and the secretion of proteolytic enzymes, the TCFA will predominate.
The histological features described above typify athero sclerotic plaques prone to acute rupture, but up to one-third of acute myocardial infarctions are precipitated by a different process 9 . Plaque erosion is caused by denudation of the plaque surface, which exposes the subintima and triggers thrombus formation. Erosion is commonly observed in young women and smokers, but despite its ubiquity, the underlying pathophysiology is poorly understood. Myeloperoxidase and increased blood thrombogenicity have been implicated as important factors in the process of plaque erosion 10 . However, identification of lesions at risk of erosion remains extremely challenging, largely because their characteristics are highly heterogeneous, and different from those associated with plaque rupture. Indeed, current imaging technology has so far not been successful in the identification of plaques at risk of erosion and the patients who have them. This shortcoming is a major limitation of risk prediction with current techniques, and an area in urgent need of further research.
Key points
• Advances in invasive and noninvasive imaging of the coronary arteries have progressed our understanding of the mechanisms underlying the precipitation of acute myocardial infarction, a leading cause of death worldwide • Imaging can provide assessments of luminal stenosis, plaque burden, plaque characteristics, disease activity, and ischaemia, generating complementary and potentially synergistic information about coronary atherosclerosis • Advances in imaging offer the potential to identify individuals at highest risk of myocardial infarction -the 'vulnerable patient'; these individuals might then be targeted with aggressive therapy to prevent future events • The next challenge is to demonstrate that these imaging techniques can have a beneficial and cost-effective effect on cardiovascular outcomes for patients with coronary artery disease Stenosis, obstruction, and ischaemia To date, imaging assessments of coronary artery disease have largely focused on detecting luminal stenosis, or obstruction to blood flow, and downstream myocardial ischaemia (FIG. 1) . These assessments are widely used to estimate patient risk and to guide revascularization. Indeed, a large body of outcome data supports this approach, demonstrating that a greater number of obstructive lesions and a larger myocardial ischaemic burden are both associated with a worse prognosis 11, 12 . However, the capacity of this paradigm to prevent myocardial infarction is increasingly being questioned.
Invasive coronary angiography
Invasive coronary angiography involves the intracoronary administration of radio-opaque contrast to opacify the lumen and delineate any existing stenoses. The presence of luminal stenoses in one, two, or three vessels is associ ated with a step-wise increase in adverse outcomes 13, 14 . However, the visual assessment of luminal steno sis correlates poorly with haemodynamic significance, particularly for coronary stenosis between 30% and 80% 15 . Although this relationship can be improved using quanti tative coronary angiography, multiple factors beyond luminal diameter, such as entrance effects, friction, and turbulence, contribute to increased flow resistance across a particular stenosis 16 . Therefore, the haemodynamic significance of lesions can be substantially underestimated or overestimated by assessment of coronary stenosis alone, particularly in the setting of multiple, eccentric, or irregular stenoses. These deficiencies have prompted the increasing use of invasive physiological assessments.
Pressure-wire-derived FFR has become the favoured technique, providing a lesion-specific surrogate measure of flow limitation derived from the difference in arterial pressure proximal and distal to a coronary lesion of interest during maximal hyperaemia. The use of FFR measurements to guide revascularization decisions seems to improve outcomes after intervention compared with standard visual estimations of stenosis 15 and has, therefore, been widely adopted, revolutionizing interventional practice around the world. In particular, FFR has helped to ensure that only those lesions causing obstruction to flow undergo intervention 15 . Coronary flow reserve (CFR) is an alternative haemo dynamic assessment, which can be performed by assessing the ratio of resting and hyperaemic flow veloci ties 16 . This approach assesses the combined effects of epicardial stenosis and microvascular disease; however, CFR has undergone less clinical validation and is less commonly performed than FFR. Catheters allowing simultaneous assessment of FFR and CFR are currently under investigation ).
Noninvasive coronary angiography
Coronary CT angiography. Technological advances in CT now allow for noninvasive imaging of the coronary arteries with high spatial resolution. Coronary CT angiography (CCTA) is performed during a breathhold using scanners with fast detector rotation times. The consequent rapid imaging times coupled with imaging during a breath-hold allows for elimination of problems relating to cardiac and respiratory motion. An extensive body of literature has evolved within a single decade, providing consistent evidence of excellent diagnostic accuracy for assessment of luminal stenoses compared with invasive angiography 18, 19 . As with invasive coronary angiography, a step-wise deterioration in prognosis associated with one-vessel, two-vessel, and three-vessel disease has been established in multiple studies using CCTA 20, 21 . CCTA has also documented the adverse prognosis associated with nonobstructive disease, and confirmed the excellent prognosis for patients with a normal CCTA, with low event rates and a 'warranty period' that extends for up to 5 years [22] [23] [24] . Although difficulty persists with CCTA in patients with advanced calcification and high heart rates, further advances in CT, including faster detector rotation times (providing 66 ms imaging with the latest technology), improved spatial resolution, and dualenergy imaging, hold promise in overcoming these and other limitations 25, 26 . The major current strength of CCTA is its negative predictive value: as high as 95% to 99% in several studies 27, 28 . Coupled with the excellent prognosis of patients found to have normal coronary arteries, CCTA is perhaps most useful in ruling out coronary artery disease in Nature Reviews | Cardiology those considered to be at low or intermediate risk. The clinical utility of this approach in the emergency department (where most patients presenting with chest pain do not have acute coronary syndrome) has been tested in several randomized, controlled trials, with a metaanalysis demonstrating that use of CCTA reduced length of hospital stay and provided cost savings, albeit with increased rates of invasive angio graphy and revascularization 29 . Similarly, two multi centre, randomized, controlled trials in patients with stable symptoms of chest pain (PROMISE and SCOT-HEART) demonstrated that CCTA provides effective risk stratification 30 , improved diagnostic accuracy 31 , reduced rates of normal coronary angiography, better-targeted therapy, and potentially reduced rates of myocardial infarction 32 . These two indications have led to the widespread and rapidly growing adoption of CCTA in routine clinical practice worldwide.
CCTA can also be used to provide a noninvasive assessment of the FFR (FFR CT ). FFR CT measurements have been evaluated in a meta-analysis, demonstrating a similar sensitivity to that of coronary CCTA (83% versus 86% per-vessel analysis) and improved specificity (78% versus 56% per-vessel analysis) in the prediction of invasive FFR 33 . FFR CT has also been reported to result in better-targeted invasive angiography, reduced referrals to the catheterization laboratory, and a lower frequency of nonobstructive disease in those patients that subsequently undergo the procedure 34 . The potential of this approach to predict the response to percutaneous intervention ('virtual stenting') has also been explored 35 .
Although of interest, FFR CT analysis is expensive and how this technology can resolve the important issues of calcium blooming (the propensity of CT to exaggerate the apparent size of calcium deposits within the vasculature) and motion artefact remains uncertain.
Coronary magnetic resonance angiography. The use of coronary magnetic resonance angiography for the assessment of coronary stenosis is attractive in principle given the avoidance of ionizing radiation. However, in practice, major challenges persist in correcting for coronary artery motion while delivering the necessary spatial resolution 36 . Therefore, although its diagnostic accuracy is improving 37 , coronary magnetic resonance angiography remains inferior to CCTA, and is rarely used in clinical practice 38 .
Myocardial perfusion imaging
In myocardial perfusion imaging (MPI), radioactive tracers are used that distribute to the myocardium according to blood flow. In particular, single-photon emission computed tomography (SPECT) and PET can be used to measure myocardial perfusion at rest and during stress, identifying regions of reversible ischaemia associated with obstructive luminal stenoses. Large-scale SPECT-MPI studies in the 1990s established a stepwise increase in mortality with progressive ischaemic burden 11, 12 , resulting in the widespread adoption of this technique to risk stratify patients and guide their management. Indeed these prognostic data, coupled with its availability and physician familiarity, remain the principal advantages of SPECT. PET-MPI is similar, but allows myocardial perfusion and the CFR to be quantified so that balanced ischaemia and microvascular disease -processes that pose limitations for SPECT -can both be detected. PET-MPI is usually performed with 82 Rb, which has an ultrashort half-life, although 13 NH 3 and 15 OH 2 can also be used with an on-site cyclotron.
Hybrid imaging refers to the combination of functional imaging using radiotracers to target specific biological processes (such as myocardial perfusion or inflammation with 18 F-fluorodeoxyglucose [FDG] ) with anatomical imaging provided by CT or MRI. Hybrid PET-CT and SPECT-CT scanners allow for CT-based attenuation correction. With these scanners, coronary artery calcification can also be routinely assessed at the time of MPI, facilitating the interpretation of perfusion scans and providing a means for detecting nonobstructive CAD 39 . Although CCTA can be combined with PET-MPI and SPECT-MPI in a single scan [40] [41] [42] , predicting in advance which patients need both studies is difficult. Further evidence of incremental clinical benefit is required in large cohorts before the increased costs and radiation exposure of this hybrid approach can be justified in routine clinical practice 39, 43 . Radiation-free MPI is increasingly being performed, particularly in Europe, using cardiac MRI, which assesses the passage of gadolinium-based contrast media through the myocardium. The recent CE-MARC trial 44 indicated that this approach offers diagnostic accuracy that is at least as high as that of SPECT. Cardiac MRI is of particular value in patients with severe coronary artery disease when additional information related to myocardial viability (delayed gadolinium enhancement) can aid clinical decisionmaking. Multiple MPI approaches are, therefore, available; deciding which to perform largely depends on local availability and expertise.
Limitations of the stenosis-ischaemia approach
The established imaging paradigm for coronary artery disease is based on the above assessments of luminal stenoses and myocardial ischaemia. Although this approach is undoubtedly effective in improving the symptomatic status of patients with angina, limitations have emerged in terms of its capacity to improve patient outcomes, leading to questions about whether we are imaging the correct target 45 . The first evidence to question this approach was the finding that the majority of lesions that go on to rupture and cause myocardial infarction were nonobstructive on antecedent angiography 46, 47 . Although an individual severe stenosis is associated with jet turbulence, reduced shear stress, and increased occlusion rates, coronary occlusion and myocardial infarction most frequently evolve from mild-to-moderate stenoses 48 . This phenomenon is largely owing to their much greater prevalence and also because mild-to-moderate lesions do not develop the protective collateral circulation often observed in severe, slowly developing stenoses.
The second piece of evidence came from randomized, controlled trials to compare percutaneous coronary intervention with optimal medical therapy in the treatment of patients with established myocardial ischaemia. Percutaneous coronary intervention effectively reduced ischaemia, but did not improve patient prognosis in either the COURAGE 49 or BARI-2D 50 studies. Similarly, in the FAME 2 study 51, 52 , the use of FFR to guide revascularization did not reduce the rate of myocardial infarction or cardiovascular death compared with medical therapy -only subsequent revascularization was reduced in the primary analysis. Therefore, although ischaemia is clearly related to symptoms, its prognostic value might actually be driven by its association with plaque burden and high-risk plaques, rather than a direct consequence of myocardial hypo perfusion. Studies showing a relationship between high-risk plaque features on CCTA and both FFR and myocardial ischaemia support this notion 53, 54 . For these reasons, and despite the prognostic data from large population studies, assessments of luminal stenosis and ischaemic burden provide imperfect prediction of hard clinical end points in individual patients. Although they remain the cornerstone of initial diagnostic strategies, awareness of these limitations has led to interest in alternative coronary imaging indices that might improve personalized patient risk assessment.
Plaque burden
Simple measures of the atherosclerotic plaque burden can be used as screening tools to assess for the presence and extent of atherosclerosis in a particular patient. Moreover, they provide powerful prognostic information, presumably on the basis that the more plaques a patient has, the greater the likelihood that one will rupture or erode and cause an event. Such measures are possible using either invasive or noninvasive technology (FIG. 2) .
Intravascular ultrasonography
IVUS involves a miniaturized ultrasound transducer to record the reflection of high-frequency sound waves, generating greyscale cross-sectional images of the arterial wall. This process provides accurate assessments of luminal dimensions and plaque volume that can aid in the evaluation of luminal stenoses, particularly in the left main coronary artery 55 . In addition IVUS can provide accurate quantification of plaque burden, acting as a powerful predictor of disease progression and adverse clinical outcomes 56, 57 . Indeed, this feature has been widely used in trials to measure the effect of medical therapies on atherosclerosis 58 . In clinical practice, however, IVUS is time consuming and invasive, and cannot be used to assess severe disease or small-vessel disease because of the fairly wide calibre of the IVUS catheter. Global plaque burden is, therefore, much more easily quantified using noninvasive approaches.
Coronary artery calcium scoring
Coronary artery calcium (CAC) scoring using electrocardiogram-gated CT provides an accurate and simple measure of the overall atherosclerotic burden in the coronary arteries. Without the need for contrast, CAC scoring quantifies macroscopic calcium within these vessels, which is pathognomonic of atherosclerosis. Although these macrocalcific plaques are themselves usually stable, the CAC score predicts prognosis probably because it provides a surrogate for the number of less-stable, adjacent plaques. Many large studies, including two large, population-based studies, have demonstrated that adding CAC scoring to Framingham Risk Scores improves the prediction of coronary events 59, 60 . The term 'the power of zero' has been described for patients with no evidence of coronary calcification using CT. The long-term prognosis of this population is so good that preventive treatment that would have been indicated by guidelines can be downscaled 61 . Multiple additional assessments have been shown to add to the standard CAC score in assessment of prognosis, including the number of vessels with calcium, the plaque location, the number of calcified plaques, the proportion of the coronary tree with plaque, the density of coronary Nature Reviews | Cardiology calcification, and plaque diffuseness 62 . Although CAC scoring using CT is increasingly being used in clinical practice, the small radiation doses are of some concern when considering repeat imaging or widespread screening programmes.
Carotid ultrasound scanning
Carotid ultrasound scanning is a well-established technique that is gaining major interest as a screening tool and method for assessing the atherosclerotic plaque burden. Despite not assessing the coronary arteries directly, carotid ultrasound scanning showed equivalent prognostic information to the use of CAC scoring when compared in the BIOIMAGE study 63 . Carotid ultrasound scanning can be used to assess the atherosclerotic plaque burden accurately, quickly (<5 min), and without ionizing radiation or the need for contrast. Moreover, the technique is inexpensive and portable, so that imaging can be readily performed outside the hospital setting. This feature is important because carotid ultrasound scanning might potentially be used for the screening of populations traditionally beyond the reach of health-care systems, including large parts of the develop ing world where rates of myocardial infarction are increasing rapidly.
Adverse plaque characteristics
Histopathological postmortem studies have consistently shown that the majority of culprit plaques responsible for plaque rupture and myocardial infarction have particular pathological characteristics, such as a thin fibrous cap, inflammation, a large necrotic core, intraplaque haemorrhage, and microcalcification. This understanding has prompted extensive clinical research over the past 20 years as investigators searched for these so-called vulnerable plaques, using each of these adverse characteristics as a potential imaging target (FIG. 3) .
Virtual histology IVUS
Virtual histology (VH)-IVUS is an invasive technique that uses spectral analysis of the ultrasound backscatter signal to categorize plaque constituents into fibrous, fibrolipidic, calcific, and necrotic tissue in real time. Other post-processing software systems have been developed, including iMAP (which uses radiofrequency signals from 40 MHz IVUS) and integrated backscatter-IVUS, but VH-IVUS remains the most widely studied 64 . Although VH-IVUS lacks the resolution to image the thin fibrous cap, lesions with necrotic core in contact with the lumen have been termed VH-TCFAs, and have moderate agreement with histology 65 . In the PROSPECT study 66 , 596 VH-TCFAs were identified in 313 out of 623 patients. Around half the lesions that went on to cause coronary events were VH-TCFAs, although the majority of these events were hospitalizations with angina. Importantly, only six patients had a subsequent myo cardial infarction, with a further 25 having a cardiac arrest or dying from a cardio vascular cause. The vast majority of these VH-TCFAs, therefore, did not result in an event and, although the positive predictive value improved if the presence of a large plaque volume (>70%) and small luminal area (<4.0 mm 2 ) were also considered, this discrimination was not high enough to justify individual plaque intervention. Similar results were observed in the VIVA trial 67 , in which >600 VH-TCFAs were identified, but only two patients subsequently had a myocardial infarction. Likewise, in the ATHEROREMO-IVUS study 68 , 242 patients had TCFAs, but only seven went on to have a myocardial infarction. The disappointing results of these three studies might, in part, indicate the tendency of VH-IVUS to overestimate the true prevalence of TCFA, as well as the exclusion of patients with severe obstructive disease who could not undergo IVUS. Nevertheless, they also point towards a more profound and general limit ation when trying to identify individual vulnerable plaques: that ultimately these plaques have a fairly low probability of themselves causing a clinical event.
Optical coherence tomography
OCT incorporates an intracoronary fibre-optic wire, which emits light in the near-infrared spectrum (wavelength 1,250-1,350 nm) and measures the backscatter from tissues during a rotational pullback along the artery 69 . Image acquisition requires the generation of a blood-free field, using small flushes of saline or contrast media 70, 71 . A particular advantage of OCT is its excellent axial resolution (12-18 µm versus 150-200 µm for IVUS), which allows detailed microstructural analy sis of the superficial plaque layers 69 . In particular, OCT allows imaging of thrombus, plaque rupture, and superficial plaque erosion with improved sensitivity compared with alternative modalities 72, 73 . OCT is also increasingly being used clinically to assess stent deployment and for post-intervention complications 74 . Detailed measurement of the fibrous-cap thickness is also possible, providing a means not only of assessing plaque vulnerability, but also of monitoring disease progression and plaque stabilization in response to therapy 75 . Interestingly, OCT (as well as IVUS) can be used in combination with computational fluid dynamics to assess local patterns of endothelial shear stress, which holds promise in improving the prediction of plaque vulnerability and progression 57, 76 . However, OCT lacks penetration, which means that although it can be used to identify necrotic core, calcification, and even macrophages 77 , the modality is not well suited to detecting these and other features beyond the superficial layers of the plaque.
Near-infrared spectroscopy NIRS relies on the phenomenon that organic molecules absorb and reflect light differently at specific wavelengths. When near-infrared light is emitted into a tissue, the spectrum of absorbance, therefore, reflects its chemical composition 78, 79 . This technique can be tuned to detect lipid within atherosclerotic plaque creat ing a 'chemogram' that can be used to identify lipid-rich lesions and quantify the lipid core burden index (LCBI) [79] [80] [81] . Combined NIRS and IVUS imaging cath eters have been used to measure both the plaque burden and the LCBI, demonstrating improved accuracy in the detection of fibroatheroma 82 . In a small cohort of patients presenting with ST-segment elevation myocardial infarction, NIRS-IVUS imaging showed that LCBI could be used to differentiate between acute culprit and nonculprit plaques 83 . Currently, this modality remains a research tool, although the capacity of hybrid NIRS-IVUS imaging to identify lipid-rich plaque and to improve cardiovascular risk prediction is currently under investigation 84 .
Coronary CT angiography
Unlike invasive coronary angiography, which visualizes only the coronary lumen, CCTA allows assessment and characterization of coronary plaque. CCTA is widely used to categorize individual plaque as being calcified, noncalcified, or mixed. Moreover, CCTA can be used to provide complete assessments of plaque burden 85, 86 , and also to identify a range of adverse plaque characteristics, including positive remodelling, low attenuation plaque, and spotty calcification. Positive remodelling Nature Reviews | Cardiology is visualized as eccentric plaque formation with relative preservation of the lumen calibre, whereas a large necrotic core is associated with very low attenuation (<30 Hounsfield units). Although true microcalcification is beyond the resolution of CT, spotty calcification has been described as a marker of early calcification and an adverse plaque characteristic 87 . Several studies have demonstrated that, compared with individuals with stable angina, patients with acute coronary syndromes have more adverse CT features [87] [88] [89] . Importantly, identifi cation of these high-risk plaque characteristics also prospectively pinpoints patients at increased risk of subsequent acute coronary syndrome. Motoyama and colleagues studied 3,158 patients using CCTA 90 . They found high-risk lesions (defined by the presence of both positive remodelling and low-density necrotic core) in 294 patients who were subsequently tenfold more likely to suffer an acute coronary syndrome than patients without such plaque (16% event rate in patients with high-risk plaque compared with 1% event rate in those without). A limitation of this approach is that the visual assessment of adverse plaque features is subjective and not highly reproducible, and manual quantitative plaque measurements are time consuming. However, automated quantification methods are in development, which have been validated against IVUS and offer promise to provide quick, accurate, and reproducible quantitative assessments [91] [92] [93] .
Cardiovascular magnetic resonance angiography
Cardiovascular magnetic resonance angiography provides excellent soft-tissue contrast and can be used to distinguish multiple high-risk plaque characteristics in the carotid artery. However, as noted above, translation into the coronary arteries has been difficult owing to problems with spatial resolution and cardiac motion. Adverse features, such as positive remodelling, can be identified in individual coronary arteries 94 . However T1-weighted imaging is the only cardio vascular MRI approach with the capacity to assess plaques across all three epicardial territories simultaneously. It uniquely targets methaemo globin, a component of acute thrombus and haemorrhage that has a very high signal on T1-weighted imaging. However, noncontrast T1-weighted MRI lacks spatial resolution and, therefore, needs to be co-registered with a dedicated coronary magnetic resonance angiogram before increased signal can be localized to the coronary vasculature. In patients with angina, high-intensity T1-weighted plaques have evidence of either subclinical plaque rupture on OCT or intraplaque haemorrhage 95 . In patients with myocardial infarction, this approach demonstrated a sensitivity and specificity of ~90% for acute thrombus at the site of culprit plaque rupture 96 . Similar to the CT data, this magnetic resonance method for high-risk plaque detection can also be used to identify patients at increased risk of cardio vascular events. Noguchi et al. studied 568 stable patients, of whom 159 were found to have high-intensity coronary plaque on T1-weighted imaging 97 . Overall, 26% of the 159 patients subsequently had an adverse coronary event, compared with 3% of the 409 patients who did not have such plaques, with high-intensity plaque emerging as a strong independent predictor of adverse events on multivariate analysis. Unlike the imaging of coronary plaque using CCTA, coronary plaque imaging with magnetic resonance remains exclusively investigational.
Vulnerable plaques and vulnerable patients
The search for the vulnerable plaque has been extensive and resource-intensive, but this approach has so far failed to change clinical care. Retrospective studies have successfully linked culprit plaque to different adverse imaging characteristics, but prospective studies have suggested that these supposedly high-risk plaques rarely go on to cause clinical events themselves 66 . The most likely explanation for this apparent discrepancy is that the vast majority of 'high-risk' plaques actually heal without rupturing. Moreover, even if rupture does occur, this event is usually subclinical, resulting in plaque growth rather than myocardial infarction 98, 99 . As a consequence, vulnerable plaques outnumber the clin ical events that they are thought to cause and, at the individual plaque-level, seem unlikely to result in myocardial infarction. Although combining multiple adverse plaque characteristics seems to improve the positive predictive value 66 , whether this improvement will be sufficient to warrant plaque-specific revascularization is the subject of considerable debate 100 .
The clinical CT and magnetic resonance outcome data described above indicate that perhaps more hope exists that vulnerable plaque identification will prove of clinical utility at the patient-level, pinpointing those individuals at highest risk of myocardial infarction. Vulnerable plaques do not occur in isolation. Indeed, multiple such plaques are often present at different sites in the vasculature 101 . Although many will heal and remain clinically silent, other plaques in different locations will also, over time, become vulnerable 102 (FIG. 3) .
Ultimately, during the course of this dynamic disease process, one such plaque might eventually rupture when the blood is sufficiently thrombogenic to trigger coronary thrombosis and myocardial infarction. Although vulnerable plaques might themselves be unlikely to cause events on a per-lesion basis, their identification can help to identify vulnerable patients with an active disease state who are at increased risk of myocardial infarction 90, 97 (FIG. 3) . Such vulnerable patients could then be targeted with aggressive systemic therapies to help to stabilize current and future high-risk plaques across the vasculature. Although attractive as a hypothesis, much work is required to assess whether such a strategy is clinically effective.
Disease activity
Increased disease activity is associated with more rapid disease progression, adverse plaque characteristics, and a poor prognosis. Both invasive and noninvasive molecular imaging techniques are being developed to measure disease activity directly within the coronary arteries (FIG. 4) . In principle, any pathological process can be targeted, subject to the availability of a suitable tracer and the relevant regulatory approvals.
Near-infrared fluorescence NIRF imaging is an emerging invasive research tool, which can be used to measure disease activity within the vasculature using fluorescent-labelled tracers 70 . Compared with conventional fluorescent imaging, NIRF utilizes the near-infrared wavelength (700-900 nm), which increases tissue penetration and the signal-to-noise ratio owing to reduced tissue autofluorescence 103 . Moreover, combined NIRF and OCT catheters have been developed that allow disease activity to be mapped onto precise anatomical images of the vasculature.
To date, the only fluorescent agent approved for human use is indocyanine green (ICG), which is used to image the retinal and choroidal vessels. ICG is a water-soluble and highly lipophilic fluorescent contrast agent, which binds to both HDL and LDL. ICG localizes to inflamed plaques in atherosclerotic rabbits and in excised human carotid endarterectomy specimens, perhaps reflecting macrophage phagocytosis of ICGbound lipoproteins 104 . Other, more specific NIRF tracers are undergoing preclinical evaluation. These include NIRF agents activated by protease activity that localize to inflamed atherosclerotic plaques [105] [106] [107] , and tracers targeting fibrin that seem to identify the initial stages of intravascular stent thrombosis 108 . Much work is required to translate this approach into humans before ultimately trying to demonstrate clinical efficacy.
Hybrid PET-CT
The activity of specific disease processes within the heart can now be measured noninvasively 109, 110 . Hybrid PET-CT systems have led the way, with the use of tracers developed largely for oncological indications 111, 112 . The first PET tracer to be widely studied in the vasculature was 18 F-FDG. This glucose analogue labels cells with high metabolic requirements, including vascular macro phages, which use more glucose than surrounding cells, particularly in hypoxic conditions 113, 114 . 18 F-FDG is most commonly assessed in the carotid arteries and aorta, where uptake correlates closely with macrophage burden, is increased in patients after myocardial infarction, and localizes to the culprit plaque after stroke 113, 115 . Indeed, this approach is increasingly being used to assess the anti-inflammatory properties of new medication in Nature Reviews | Cardiology phase II clinical trials, accurately mirroring their clinical efficacy [116] [117] [118] . Finally, preliminary studies have suggested that the large-vessel 18 F-FDG signal might provide independent prognostic information. A retrospective study of 513 patients who underwent PET imaging for oncological evaluation (but ultimately did not have cancer or inflammatory disease) showed that aortic 18 F-FDG uptake provided independent prediction of cardiovascular events after a median of 4.2 years of follow-up (HR 4.71, P <0.001) 119 . Similarly in 1,089 asymptomatic adults being screened for cancer, increased carotid 18 F-FDG uptake predicted future stroke with incremental value above the Framingham Risk Score 120 . Interpretation of these data is limited by the patient popu lations studied. However, the large BIOIMAGE study 121 will address this issue in a prospective cohort of patients with cardiovascular risk factors and help to inform as to whether this technique has a role in clinical practice.
Unfortunately, application of 18 F-FDG PET plaque imaging to the coronary arteries has proved challenging 122, 123 , largely because glucose is the predominant energy source of the myocardium and, as a consequence, 18 F-FDG uptake in the left ventricle frequently obscures activity within the coronary arteries 124 . Interest has, therefore, grown in the potential use of alternative, more-specific PET tracers. One such alternative is 18 F-fluoride, a positron-emitting tracer that binds preferentially to regions of vascular microcalcification beyond the resolution of CT 125 . In so doing, 18 F-fluoride can be used to detect areas of newly developing vascular and valvular calcification. Indeed, in the valves of patients with aortic stenosis, 18 F-fluoride uptake can be used to identify where new macroscopic deposits of calcium are going to develop, and to predict disease progression 109, 126 . In carotid atheroma, 18 F-fluoride uptake localizes to culprit plaques and is again associated with histological markers of calcification activity as well as cell death and inflammation 124 . In the coronary arteries, increased 18 F-fluoride can be localized to individual coro nary plaques with little background uptake, identify ing patients with a high Framingham Risk Score 127 , and plaques with multiple adverse features on VH-IVUS and CT (microcalcification, positive remodelling, necrotic core) 124, 128 . Importantly, 18 F-fluoride also precisely localizes to the culprit plaque in ~90% of patients with recent myocardial infarction, although absolute uptake in this cohort is not as high as in patients with stable disease 124, 129 . Although this early research is limited by small numbers of patients, the capacity of 18 F-fluoride PET to prospectively identify patients at increased risk of myocardial infarction is currently the subject of the large, multicentre, observational PREFFIR study 130 of 700 patients. These studies have demonstrated the feasibility of PET imaging in the coronary arteries and that assessing disease activity in these vessels is possible. Moreover, rapid advances in scanner technology and image analy sis software now allow PET images to be electrocardiogram-gated and respiratory-gated, and then co-registered with contrast CT scans. This processing allows more-precise localization of the PET signal within the coronary tree 124 , which can be further improved with advanced motion-correction image analy sis 131 (FIG. 4) .
This approach, therefore, looks set to be of major utility in the research environment, particularly if novel tracers can be successfully developed. Alternative, more-specific PET tracers for inflammation are being investigated, including 68 Ga-dotatate, which is already approved for human use, and 18 F-fluorodeoxymannose, which is not 132, 133 . The advent of PET-MRI also promises progress, particularly in relation to reduced radiation exposure 134 , which is high with PET-CT and might ultimately limit its clinical uptake.
Multiparametric imaging
Imaging markers of luminal stenosis, myocardial ischaemia, plaque burden, adverse plaque characteristics, and disease activity provide complementary information about coronary atherosclerosis -itself a complex, multi faceted condition. Novel imaging approaches combining these different factors might deliver not only pathological insight, but also major improvements in cardiovascular risk prediction. Early evidence supports this hypothesis. In a study by Motoyama et al., the presence of high-risk CT plaque characteristics identified patients more likely to have an acute coronary syndrome, but risk prediction was improved when the presence of an obstructive coronary lesion was added to the model 90 . Indeed, patients positive for both measures had an acute coronary syndrome event rate of >25% at 4 years -arguably high enough to justify aggressive and expensive treatment strategies. Similarly in the PROSPECT 66 , VIVA 67 , and ATHEROREMO-IVUS 68 studies, combining the presence of a TCFA with a luminal area <4 mm 2 and a high plaque burden led to a step-wise improvement in prognostication, albeit largely related to subsequent revascularization procedures. Imaging modalities that can be used to evaluate multiple different atherosclerotic plaque characteristics in a single scan, therefore, hold considerable potential advantages, as do imaging strategies involving more than one modality.
Evolution of novel imaging strategies
The treatment of coronary artery disease has two major focuses. The first is the identification and relief of anginal symptoms (FIG. 5) . The second is to identify patients at increased risk of myocardial infarction so that preventive treatments can be introduced and adverse events averted (FIG. 6) . These treatments include lifestyle measures, simple medical interventions (such as aspirin and statins), the treatment of risk factors, and CABG surgery in patients with left main stem or multivessel disease. We now also have novel agents, in particular PCSK9 inhibitors, that dramatically lower LDLcholesterol levels, have minimal adverse effects, and are widely antici pated to be highly efficacious. However, these drugs are also extremely expensive. Their use will, therefore, require careful targeting to those at highest risk, leading to an important potential application of improved risk-stratification methods.
Imaging plaques
The current paradigm of coronary imaging is based around the detection of discrete areas of obstructive luminal stenoses and the myocardial ischaemia that these cause. Although this approach remains of major utility in the relief of angina, percutaneous coro nary intervention guided by these approaches has consistently failed to reduce the incidence of myocardial infarction. Strategies based around identifying individ ual vulnerable plaques have proved similarly ineffective, being limited by the relative ubiquity of these lesions compared with clinical events. Therefore, despite extensive time, effort, and financial investment, imaging strategies targeting individual plaques have largely failed to improve the natural history of atherosclerosis.
Imaging patients
An imaging strategy that instead assesses the atherosclerotic disease process across multiple plaques and territories might prove more effective. Crucially, this approach need not rely on pinpointing the individual plaque that will cause an event. Rather, it focuses upon identifying vulnerable patients with extensive atherosclerosis, increased disease activity, and multiple high-risk plaque characteristics, who are at increased overall risk of an adverse cardiovascular event. These plaques can occur anywhere in the coronary or, indeed, the carotid circulation. The positive predictive value of such a patient-oriented approach is, therefore, likely to be considerably higher than an individual-plaque strategy, allowing treatment decisions to be made with greater confidence of benefit. Moreover, this approach is more closely aligned to the systemic treatments already known to improve prognosis.
How might such a strategy work? We would advocate a tiered approach using simple, cheap tests for initial screening, followed by more-complex scans that would progressively refine patient risk-stratification and direct treatment. One of many potential approaches is outlined here, and clearly requires intensive investigation before it could be recommended. This strategy would involve screening with carotid ultrasonography or CAC scoring as the first step to identify patients with atherosclerosis and those with advanced plaque burden. This information could then be used to direct lifestyle interventions, and the targeted prescription of simple medication, such as statins and aspirin. Focused screening in high-risk or disadvantaged communities might help to maximize cost-effectiveness and clinical results. Patients found to have advanced plaque burden would then proceed to more-advanced noninvasive imaging approaches. We would currently advocate CCTA given that it can be used to assess coronary plaque burden, luminal stenosis, and high-risk plaque characteristics simultaneously, combined with the emerging prognostic data supporting combined assessment of these factors. Patients deemed at high-risk on this scan could then be targeted with intensive and potentially expensive therapies, as appropriate (such as PCSK9 inhibitors, dual antiplatelet therapy, revascularization). In patients with extensive coronary calcification, renal failure, or known coronary artery disease, ischaemia testing might be used for further risk stratification and helping to guide revascularization decisions.
With future imaging development, further tiers of stratification could be added. For example, PET imaging could be used in those with adverse CT findings to measure disease activity and to differentiate between patients with active versus burnt-out stable atheroma. Invasive imaging would be reserved for those patients being considered for revascularization, in whom advanced imaging might help to guide and optimize this procedure.
Barriers to future implementation
The past 10-15 years have witnessed a remarkable expansion in cardiovascular imaging technology, but considerable work is still required to translate these advances into improved clinical practice. Perhaps the major challenge is demonstrating that these approaches can truly deliver personalized patient management and improved outcomes. Although mechanistic and observational data are an important part of that process, randomized, controlled trials will be essential to confirm the clinical efficacy of any new imaging modality or strategy. After initial clinical assessment, symptomatic patients with suspected angina can be assessed using noninvasive imaging modalities (either CT or perfusion imaging depending on local expertise) to identify the presence and extent of perfusion abnormalities or obstructive luminal stenoses. These results can then be used to risk stratify and guide the prescription of medical therapy. In patients identified as being at high risk (for example, by the presence of three-vessel disease or a large ischaemic burden), or in those with recalcitrant symptoms, invasive coronary angiography should be performed with adjuvant fractional flow reserve (FFR) or intravascular ultrasonography (IVUS) as necessary. These tests can then guide the need for revascularization by percutaneous coronary intervention or CABG surgery. CCTA, coronary computed tomography angiography; CMR, cardiovascular magnetic resonance; PET, positron emission tomography; SPECT, single-photon emission computed tomography.
Another important issue is that imaging is expensive, particularly when compared with risk-factor assessments and blood biomarkers. The cost-effectiveness of any imaging strategy must be carefully evaluated and demonstrated to be the equivalent of simpler methods. Moreover, combined approaches using risk factors and blood biomarkers (such as troponin levels measured by high-sensitivity assay) to select subsequent imaging are attractive and should be explored carefully.
The radiation exposure associated with CT and nuclear imaging must also be considered. In particular, this exposure is a major concern for any strategy likely to involve repeated scans over a patient's lifetime. In this context, the development of low-radiation and radiation-free imaging remains an important, but challenging, goal. Importantly, technological improvements are leading to marked reduction in radiation dose with CCTA as well as with nuclear techniques. Indeed, the average radiation dose from CCTA with current scanners and protocols is approaching 1 mSv 135 -one-third of that coming from annual background radioactivity. Finally, mechanistic studies to improve the remaining gaps in our pathophysiological understanding are crucial. In particular, the concept of plaque erosion needs to be further investigated, and imaging methods developed to improve prediction of this important pathological process.
Conclusions
Advances in cardiac imaging now allow coronary atheroma to be visualized directly using both invasive and noninvasive strategies. Imaging modalities can provide detailed and complementary information with respect to disease burden, luminal stenoses, myocardial ischaemia, adverse plaque characteristics, and disease activity. This information has already greatly improved our understanding of the disease process, but considerable work remains to translate this information into accurate risk-prediction tools and improved clinical care and outcomes for our patients with coronary artery disease. Figure 6 | Possible approach using multimodality imaging to risk stratify patients with atherosclerosis. Advances in imaging technology now allow multiple different atherosclerotic features to be assessed using both invasive and noninvasive technology. The challenge is to use these advances to improve patient risk stratification, guide clinical management, and ultimately reduce adverse cardiovascular events. A possible future approach to patient assessment and risk stratification is presented. Initial screening with risk-factor assessment and simple strategies to measure plaque burden can be used in large populations to guide lifestyle interventions and the prescription of aspirin and statins. In those with advanced plaque burden, more-advanced imaging using assessments of luminal stenosis, myocardial ischaemia, and plaque characteristics can then be used to identify those at the highest risk of future events. Combined information is likely to provide complementary results. These vulnerable patients could then be targeted with powerful but expensive systemic therapies that are emerging (such as PCSK9 inhibitors) or dual antiplatelet therapy, where the potential for bleeding might be outweighed by the high cardiovascular risk. As additional data emerge, the use of hybrid imaging (such as PET-CT) might further refine advanced noninvasive risk stratification, differentiating patients with active disease from those with 'burnt out' stable atheroma. Finally, in patients being considered for revascularization, advanced invasive imaging including fractional flow reserve (FFR) and other emerging approaches can be used to optimize decisions regarding percutaneous intervention or CABG surgery. CCTA, coronary computed tomography angiography; FFR CT , fraction flow reserve measured by CCTA; IVUS, intravascular ultrasonography; NIRF, near-infrared fluorescence; NIRS, near-infrared spectroscopy; OCT, optical coherence tomography; SPECT, single-photon emission computed tomography.
